"label","rationale","id","name","instanceType","description","uuid:ID"
"","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","Study Design 1","StudyDesign","The main design for the study","92a08e17-be94-435f-b875-14e0b2cadd29"
